Dr. John Cush RheumNow
2 years 11 months ago
FDA Approves Infliximab Biosimilar for Subcutaneous Use
Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease.
https://t.co/oTGm16k6Uo https://t.co/tSysmriP7q https://t.co/TIZc8rxwxM
Dr. John Cush RheumNow
2 years 11 months ago
JAMA Review of Knee Pain:
- 5% PCP visits for knee pain:
- Knee #OA: 654 mill worldwide, mostly >45 yrs age
- Patellofemoral OA: < 40 yrs age; Sx: ant knee pain w/ squat
- Meniscal tears: 12% adults < 40 yrs; dx by McMurray test & joint line tenderness
https://t.co/AKVFXjY0D8 https://t.co/GpBxA2rdLP
Dr. John Cush RheumNow
2 years 11 months ago
JAKi Safety and Efficacy in bDMARD-IR Patients with RA: Results Through 5 Years
Now in the RheumNow poster hall: Long-term extension outcomes from SELECT-BEYOND through 5 years in bDMARD-IR patients with RA. Sponsored by AbbVie US Medical Affairs. https://t.co/07PrYidnt9 https://t.co/qWM9N68hZ1
Dr. John Cush RheumNow
2 years 11 months ago
Check out the latest therapeutic update for axSpA in this video series dedicated to creating a better understanding of treatment goals.https://t.co/8zFMwt5Q7g https://t.co/tc9txlCgw8
Dr. John Cush RheumNow
2 years 11 months ago
PMR Mythbusters: PMR Gets 100% Better Within 72 hours
https://t.co/S7PWlNoQez https://t.co/CN469rzGVl
Dr. John Cush RheumNow
2 years 11 months ago
Cardiovascular and VTE Risk w/JAKi Treatment of Skin Disorders
A JAMA systematic review and meta-analysis has shown the use of JAKi in immune-mediated inflammatory skin diseases was not associated w/ increased risk of all-cause mortality, MACE, or VTE.
https://t.co/XYAeLnFvHr https://t.co/tGRNEUEZj9
Dr. John Cush RheumNow
2 years 11 months ago
Optimal Management of DQT
The treatment of DQT was examined by systematic review in JAMA, suggesting that local corticosteroid injection + a thumb spica immobilization was associated w/significant pain-relieving and functional benefits.
https://t.co/1437g9ylZy https://t.co/TTlF28oa1S
Dr. John Cush RheumNow
2 years 11 months ago
Study of LATE-onset RA (>65y), shows DMARD initiation is low in LORA; despite current clinical practice guidelines recommending early aggressive Rx. Among 3,373 LORA pts (age77 yrs), only 29% initiated on a DMARD (28.9%). https://t.co/bWHaiiSMVl https://t.co/NmrDeG8UPW
Dr. John Cush RheumNow
2 years 11 months ago
Fast track clinics -the future of #PMR care?
As the month dedicated to PMR draws to a close, we begin to look to the future, and what the ideal management of PMR looks like.
https://t.co/F4oRPnKWhe https://t.co/1yoUNaQqW5
Dr. Jack Cush reviews the news, journal reports and regulatory approvals from the past week on RheumNow.com.
Study of LATE-onset RA (>65y), shows DMARD initiation is low in LORA; despite current clinical practice guidelines recommending early aggressive Rx. Among 3,373 LORA pts (age77 yrs), only 29% initiated on a DMARD. https://bit.ly/47dT6x6
JAK inhibitors are known to increase the risk of herpes zoster infections between between 3-5 fold. Two recent reports suggest variable efficacy when JAK inhibitor (JAKi) treated patients are vaccinated with the recombinant herpes zoster subunit vaccine (RZV).
Safety risks found in a postmarketing trial with the Janus-associated kinase (JAK) inhibitor tofacitinib (Xeljanz) appear to have influenced prescribing patterns across the class for rheumatoid arthritis (RA) patients in the Veterans Affairs (VA) health system, researchers found.
Dr. John Cush RheumNow
2 years 11 months ago
Study of TNFi tapering in 108 axSpA patients in remission. Gradual tapering over 2 yrs resulted in flares in 99% (108).
- 27% flared at 2/3 dose
- 20% at 1/2 dose
- 27% at 1/3 dose
- 25% w/ discontinuation
WHY WOULD YOU DO THIS? I DONT! https://t.co/mIJKaK3LK5 https://t.co/SMGJVfepTl
Dr. John Cush RheumNow
2 years 11 months ago
256 Early RA pt cohort followed 10yrs showed SDAI sustained remission(n 48) had less 10 yr Xray progression (mTSS 4.06), vs sustained LDA (14.6) or MDA/HDA (21.04). Sustained remission pts were younger, lower HAQ & mTSS scores; less need for GC & bDMARDs https://t.co/92L7RTCx82 https://t.co/4uZBydcfRM
